What is the central legal question before the California Supreme Court in the Gilead case?

The central legal question is whether drug manufacturers have a legal 'duty to innovate'—specifically, whether they can be held liable in negligence for deciding not to develop or commercialize an alternative drug (TAF) that allegedly had fewer side effects than their approved, FDA-cleared drug (TDF), even though TDF itself is not alleged to be defective.

Why did Gilead discontinue development of TAF in 2004, and what do plaintiffs allege was the real reason for delaying its release?

Gilead discontinued TAF development in 2004, stating its effectiveness and safety were not meaningfully different from TDF to justify further investment; plaintiffs allege Gilead instead delayed TAF’s commercialization to avoid cannibalizing TDF sales and to maximize profits until TDF’s patent expired in 2017, thereby earning billions in additional revenue from tenofovir-containing drugs after that date.

California's Highest Court to Consider Whether Drugmakers Have 'Duty to Innovate'

May 6, 2026

The California Supreme Court will hear arguments on whether drugmakers face a legal 'duty to innovate,' specifically in a Gilead Sciences case involving HIV medication development delays. A ruling could significantly alter product liability laws and impact pharmaceutical R&D strategies.

reuters

2026-05-06

California's Highest Court to Consider Whether Drugmakers Have 'Duty to Innovate'

2026-10-22

Gilead to Acquire PepStar's Inflammation Drug Program in $1.28 Billion Deal

California's Highest Court to Consider Whether Drugmakers Have 'Duty to Innovate'

FAQ